Abstracts

310 – Dual IL-21/IL-15 Enhances CD8 T- and NK-Cell Function, Promoting Viral Control Post-ART Interruption

Background HIV persistence within cellular and anatomical viral reservoirs remains the primary barrier to a cure for HIV, with virus rebounding upon ART interruption (ATI) in most people with HIV. As such, developing interventions aimed at improving immune responses is a key priority for HIV cure strategies. Here, we investigated the effects of a combined heterodimeric…

583 – Islatravir and Ulonivirine Create a Combination With a High Barrier to Resistance In Vitro

Background Islatravir (ISL) is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) in clinical development in combination with ulonivirine (ULO), a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), for once-weekly oral treatment of HIV-1. Resistance selection studies were performed in vitro to assess the barrier and pathways for the emergence of resistance to the combination. Methods…

1050 – Impact and Cost-Effectiveness of Geographic Prioritization for Delivery of Long-Acting PrEP

Background Long-acting injectable pre-exposure prophylaxis (PrEP), including Lenacapavir, offers an opportunity to accelerate HIV incidence declines in southern and eastern Africa. Given constrained HIV budgets, competing needs for health resources, and high product and delivery costs, prioritization strategies are needed to maximize HIV prevention impact and deliver value with limited health resources.  Methods We used…

1058 – Coverage and Discontinuation of Long-Acting Cabotegravir vs Oral PrEP in the Italian PrIDE Cohort

Background PrEP with oral tenofovir disoproxil fumarate/emtricitabine (F/TDF) may be frequently discontinued or poorly adhered to. Long-acting cabotegravir (CAB-LA) may overcome adherence challenges and enhance prevention coverage. Evidence from European real-world settings is lacking. Methods All PrEP users (PrU) enrolled in the PrIDE cohort from December 2024 (date of CAB availability) to August 15, 2025…

607 – Baseline Plasma and T-Cell Immune Profiles Linked to Liver Stiffness Regression After HCV Cure

Background Liver fibrosis regression after hepatitis C virus (HCV) cure is variable, especially in advanced cirrhosis. Despite >95% sustained virological response (SVR) rates with direct-acting antivirals (DAAs), long-term risks of decompensation and hepatocellular carcinoma persist, suggesting an “immunological scar.” Determinants of regression remain unclear, particularly in HIV coinfection. We aimed to identify baseline plasma and…

332 – The Plasma Cell–Free DNA Methylome Predicts Intact HIV Reservoir Decay During Antiretroviral Therapy

Background Identifying non-invasive biomarkers of HIV persistence is critical to the development and evaluation of cure strategies. Cell-free DNA (cfDNA), largely released into circulation by dying cells, has proven to be an invaluable biomarker in the oncology space. We recently demonstrated that plasma-derived cfDNA levels and epigenetic features predict HIV rebound kinetics following antiretroviral therapy…

358 – Chimeric Virus-Host Transcripts Reveal Integration Sites in Macaque SIV+ CD4 T Cells

Background Elucidating mechanisms governing proviral integration and transcription may aid in identifying strategies to limit HIV-1 reservoirs.  Chimeric host-viral transcripts are a mechanism by which HIV-1 modulates host gene expression to promote reservoir persistence, though they are poor characterized in vivo.  We analyzed SIV RNA+ CD4 T cells for viral, host, and chimeric transcripts during…

1095 – Hair and Point-of-Care Tenofovir Urine Self-Collection Feasible With Urine TFV Predicting Viral Load

Background Resurgent stimulant use among men who have sex with men (MSM) with HIV contributes to antiretroviral therapy (ART) adherence challenges. Objective monitoring of ART adherence and stimulant use via drug-level testing can inform interventions, surveillance, and future research. We developed a rapid, low-cost urine point-of-care (POC) tenofovir (TFV) assay as an objective adherence metric.…

661 – Multiomics Analysis of Oral Microbiome and Atherosclerosis in Women and Men With HIV

Background Although alterations in gut microbiota have been implicated in both HIV and atherosclerotic cardiovascular disease, the role of the oral microbiota remains less understood, particularly its potential connections to host immunity and inflammation in the context of HIV. Methods We examined associations of oral microbial features measured by 16S rRNA sequencing with carotid artery plaque(focal intima-media thickness >1.5 mm) assessed by B-mode ultrasound in…